You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Inclisiran

Showing 1 - 25 of 33
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Inclisiran on Major Adverse Cardiovascular Events in French

Not yet recruiting
  • Atherosclerotic Cardiovascular Disease
  • Inclisiran sodium
  • +3 more
  • (no location specified)
Jul 26, 2023

Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)

Not yet recruiting
  • Primary Hypercholesterolemia or Mixed Dyslipidemia
  • Inclisiran
  • Matching Placebo for Inclisiran
  • (no location specified)
May 24, 2023

Hypercholesterolemia Trial (Inclisiran, Ezetimibe, Matching Placebo for Inclisiran)

Not yet recruiting
  • Hypercholesterolemia
  • Inclisiran
  • +3 more
  • (no location specified)
Feb 28, 2023

Inclisiran Among Early Users in Germany

Completed
  • High Levels of Low-density Lipoprotein Cholesterol
    • Basel, Switzerland
      Novartis
    May 12, 2023

    Primary Prevention of Atherosclerotic Cardiovascular Disease Trial (Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran)

    Not yet recruiting
    • Primary Prevention of Atherosclerotic Cardiovascular Disease
    • Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
    • Placebo in 1.5ml
    • (no location specified)
    Feb 13, 2023

    The Belgian REAL (BE.REAL) Registry

    Not yet recruiting
    • Atherosclerotic Cardiovascular Disease
    • Inclisiran
    • (no location specified)
    Feb 3, 2023

    Heterozygous or Homozygous Familial Hypercholesterolemia Trial (Inclisiran)

    Not yet recruiting
    • Heterozygous or Homozygous Familial Hypercholesterolemia
    • Inclisiran
    • (no location specified)
    Dec 27, 2022

    German Inclisiran Network: Retrospective Registry of Patients

    Recruiting
    • Hypercholesterolemia
      • Jena, Germany
        Jena University Hospital
      Jul 4, 2022

      Inclisiran Plus Standard of Care Lipid-lowering Therapy Compared

      Recruiting
      • Primary Hypercholesterolemia
      • Mixed Dyslipidemia
      • Inclisiran
      • Geneve 14, Switzerland
        Novartis Investigative Site
      Nov 14, 2022

      Inclisiran in Chinese Adult Primary Hypercholesterolemia or

      Recruiting
      • Primary Hypercholesterolemia
      • Mixed Dyslipidemia
      • Inclisiran
      • Haikou, Hainan, China
      • +2 more
      Jun 13, 2022

      Hypercholesterolemia, Atherosclerotic Ischemic Disease Trial in Heidelberg, London (lerodalcibep, Inclisiran)

      Enrolling by invitation
      • Hypercholesterolemia
      • Atherosclerotic Ischemic Disease
      • lerodalcibep
      • Inclisiran
      • Nantes, Cedex 01, France
      • +6 more
      Nov 3, 2022

      Hyperlipidemia Trial in Changsha, Chengdu, Beijing (100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran), Placebo, 300 mg

      Completed
      • Hyperlipidemia
      • 100 mg inclisiran sodium (equivalent to 94.5 mg inclisiran)
      • +2 more
      • Changsha, Hunan, China
      • +2 more
      Dec 2, 2021

      Atherosclerotic Cardiovascular Disease Trial in Boston, Oxford (Inclisiran, Placebo)

      Recruiting
      • Atherosclerotic Cardiovascular Disease
      • Inclisiran
      • Placebo
      • Boston, Massachusetts
      • +1 more
      Mar 1, 2022

      Atherosclerotic Cardiovascular Disease, Atherosclerotic Cardiovascular Disease Risk Equivelents, Elevated Low Density

      Active, not recruiting
      • Atherosclerotic Cardiovascular Disease
      • +2 more
      • Inclisiran
      • Behavioural Support
      • Sale, Cheshire, United Kingdom
      • +16 more
      Jan 20, 2023

      Qualitative Features of Atherosclerotic Plaques

      Active, not recruiting
      • Atherosclerotic Cardiovascular Disease
      • Inclisiran
      • Riga, Latvia
        Pauls Stradins Clinical University Hospital
      Dec 5, 2022

      Atherosclerotic Cardiovascular Disease Trial in United States (Inclisiran)

      Recruiting
      • Atherosclerotic Cardiovascular Disease
      • Inclisiran
      • Little Rock, Arkansas
      • +43 more
      Jan 20, 2023

      LDL-cholesterol Trial in Jena (statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran)

      Recruiting
      • LDL-cholesterol
      • statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran
      • Jena, Thuringia, Germany
        University Hospital Jena
      Oct 17, 2022

      Hypercholesterolemia, Hypercholesterolemia, Familial Trial in Cambridge (PCSK9 inhibitor, 68Ga-DOTATATE PET-MRI)

      Not yet recruiting
      • Hypercholesterolemia
      • +3 more
      • Inclisiran
      • +2 more
      • Cambridge, United Kingdom
        University of Cambridge
      Jan 13, 2023

      sessmenT and treAtment In AustraliaN Primary Care

      Not yet recruiting
      • Atherosclerotic Cardiovascular Disease (ASCVD)
      • +3 more
      • Inclisiran Prefilled Syringe
      • Clayton, Victoria, Australia
        Monash Health
      Apr 17, 2023

      Familial Hypercholesterolemia - Heterozygous Trial in Worldwide (Inclisiran, Placebo)

      Recruiting
      • Familial Hypercholesterolemia - Heterozygous
      • Inclisiran
      • Placebo
      • Tucson, Arizona
      • +76 more
      Aug 8, 2022

      Inclisiran and Other Lipid Lowering Treatments inReal-world

      Recruiting
      • Hypercholesterolemia
      • Inclisiran
      • Freudenstadt, Baden Wuerttemberg, Germany
      • +94 more
      Jan 24, 2023

      Coronary Artery Disease Trial in Worldwide (Inclisiran sodium 300 mg, Placebo)

      Recruiting
      • Coronary Artery Disease
      • Inclisiran sodium 300 mg
      • Placebo
      • Huntsville, Alabama
      • +54 more
      Jan 31, 2023

      Hypercholesterolemia Trial in Worldwide (inclisiran sodium, Placebo)

      Active, not recruiting
      • Hypercholesterolemia
      • inclisiran sodium
      • Placebo
      • Lanzhou, Gansu, China
      • +44 more
      Feb 7, 2022

      Acute Coronary Syndrome Trial in United States (Inclisiran)

      Recruiting
      • Acute Coronary Syndrome
      • Inclisiran
      • Huntsville, Alabama
      • +77 more
      Jan 13, 2023

      Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes Trial in Worldwide (Inclisiran, Evolocumab)

      Completed
      • Atherosclerotic Cardiovascular Disease
      • +3 more
      • Jacksonville, Florida
      • +51 more
      Feb 7, 2022